(VIANEWS) – KID (KID.OL), VISTIN PHARMA (VISTN.OL), SCANA (SCANA.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. KID (KID.OL)
7.8% sales growth and 26.8% return on equity
Kid ASA, together with its subsidiaries, operates as a home textile retailer in Norway, Sweden, Finland, and Estonia. It designs, sources, markets, and sells a range of home and interior products, including textiles, curtains, bed linens, home accessories, decorations, furniture, and other interior products through retail stores and online platforms. The company provides its products under the Kid, Hemtex, Dekosol, Nordun, and Premium Collection brands. It also offers logistics services. The company was formerly known as Nordisk Tekstil Holding AS and changed its name to Kid ASA. Kid ASA was founded in 1937 and is headquartered in Lier, Norway.
Earnings Per Share
As for profitability, KID has a trailing twelve months EPS of kr8.64.
PE Ratio
KID has a trailing twelve months price to earnings ratio of 17.2. Meaning, the purchaser of the share is investing kr17.2 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.8%.
Moving Average
KID’s value is above its 50-day moving average of kr147.44 and way above its 200-day moving average of kr119.32.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on May 21, 2024, the estimated forward annual dividend rate is 9.25 and the estimated forward annual dividend yield is 6.22%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 52.2% and 7.2%, respectively.
More news about KID.
2. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 19.84% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.27.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 17.56. Meaning, the purchaser of the share is investing kr17.56 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.84%.
Moving Average
VISTIN PHARMA’s worth is below its 50-day moving average of kr22.94 and below its 200-day moving average of kr22.98.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Nov 6, 2024, the estimated forward annual dividend rate is 1.75 and the estimated forward annual dividend yield is 7.71%.
More news about VISTIN PHARMA.
3. SCANA (SCANA.OL)
5.7% sales growth and 18.92% return on equity
Scana ASA engages in the offshore, energy, and maritime businesses in Norway, rest of European countries, America, Asia, Africa, and Oceania. The company offers valve remote control systems and mooring solutions to vessels, rigs, and floating structures serving the shipping, aquaculture, oil and gas, and energy industries. It also engages in the design and integration of electrical power systems, electrical infrastructure, and energy storage systems and control systems. In addition, the company is involved in the planning and execution of insulation, scaffolding, and surface treatment services; and rig, capping, equipment support, make and break, IMR lifecycle, welding, and asset integrity management services to drilling industry, as well as offers riser applications to the oil and gas industry. Scana ASA was formerly known as Incus Investor ASA and changed its name to Scana ASA in May 2020. The company was founded in 1646 and is headquartered in Bergen, Norway.
Earnings Per Share
As for profitability, SCANA has a trailing twelve months EPS of kr0.22.
PE Ratio
SCANA has a trailing twelve months price to earnings ratio of 9.2. Meaning, the purchaser of the share is investing kr9.2 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.92%.
Sales Growth
SCANA’s sales growth is 35% for the present quarter and 5.7% for the next.
More news about SCANA.
